clairop

How Often Do People Switch Biologics for Crohn's?

About half of people starting a biologic for IBD switched or swapped within 5 years in an Italian study. What the real-world numbers say, and why.

Clairop Team21 min read

Photo: Queensland, Australia / Unsplash

The short answer

Switching is common but not the norm for everyone. In a study of 28,073 Italian people starting a biologic for IBD, 12% switched or swapped within 1 year, 36% within 3 years and 53% within 5 years, and about 1 in 5 changed more than once. Rates differ by drug, definition and country.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Switching biologics for Crohn's disease is common, but it is not a rule that everyone follows. Switching means moving from one biologic (a protein medicine such as infliximab, adalimumab, vedolizumab or ustekinumab) to another. In an Italian database of 28,073 people starting a biologic for IBD, 12% had switched or swapped by year 1, 36% by year 3 and 53% by year 5, and about 1 in 5 had changed more than once (Pellegrini 2025). Others stay on one drug for many years.

That wide spread is the honest answer, and it is why forum threads on this question look so contradictory. This article collects the real-world numbers in one place: how often people switch, how many drugs people go through, why they switch, and what trials and registries show about how the next drug performs. It describes evidence. It is not advice to change, stop or hold off on any medicine, and every one of those decisions belongs to you and your IBD team.

Timing matters before any switch conversation, so read how long Crohn's biologics take to work for the usual assessment windows.

How often do people switch biologics for Crohn's disease?

Roughly one in eight people changes drug in the first year and about half within five years in the largest dataset we found, but the figures shift with how a study defines a "switch" and who it follows. The Italian VALORE network followed first-ever biologic users from 2010 to 2023 and counted both switches (to the same class) and swaps (to a different class) (Pellegrini 2025).

Follow-upSwitched or swapped at least once
1 year12.0%
3 years35.6%
5 years52.6%
Changed 2 or more times by 5 years18.7%

Three cautions apply. First, this cohort mixes Crohn's disease (55.8%) and ulcerative colitis (44.2%), and we did not find the table split out for Crohn's alone in the published abstract. Second, it is based on pharmacy and administrative records, so it shows what was dispensed, not why. Third, the study also tracked moves from an original brand to a biosimilar (a near-copy of it), and changes like that can be administrative decisions rather than a drug failing. In that study, 10% of people who moved from an originator to a biosimilar of the same molecule later went back to the originator. If several have already failed, see what to do when all biologics fail for Crohn's.

The same Italian paper found that anti-TNF drugs (infliximab and adalimumab) switched more often and sooner than vedolizumab or ustekinumab. Depression and corticosteroid use were linked to multiple switches by year 3. These are associations in administrative data. They do not show that depression or steroids cause switching.

Other databases give different pictures:

  • Denmark, national registers, 2015 to 2020: 3,028 people with Crohn's started a first biologic, 85% of them on infliximab. The authors report that one in four people with UC or Crohn's experienced more than one biologic during the study period (Jensen 2023).
  • US insurance database (Optum), 2017 to 2022: of 11,992 adults with UC or Crohn's starting a biologic, 1,293 (about 11%) underwent a switch during follow-up (Kruger 2025). The study window was about five years and not everyone was followed for all of it, which is one reason the share is lower.

Put together, the pattern is consistent even when the percentages are not: a meaningful minority switches early, about half switch within five years in some data, and a large group stays on its first drug for a long time. If you are on your first biologic and it is working, that is not unusual.

How long do people stay on their first biologic?

Time on a first biologic ranges from about a year in selected groups to many years in unselected ones. In a US claims study of 2,309 people with Crohn's starting a biologic, 3-year persistence (still on the drug, without a gap long enough to count as stopping) was 48.1% for infliximab, 52.1% for adalimumab, 58.0% for vedolizumab and 61.4% for ustekinumab (Zhao 2023). Related: can you stop Crohn's medication in remission?

Drug (first claim 2016 to 2018)Still on drug at 3 yearsStopped with no switch or restart
Infliximab48.1%28.1%
Adalimumab52.1%37.3%
Vedolizumab58.0%25.3%
Ustekinumab61.4%30.7%

Read this table carefully. It is observational, drawn from commercially insured adults, and the authors did not adjust for differences between the groups. People who get a given drug may differ in how severe their disease is and what they have already tried. Ustekinumab users in this study also had more other health conditions on average. So the table says what happened in this claims database, not which drug is better. A Danish national study that did adjust for some factors found adalimumab as first biologic carried a higher risk of discontinuation than infliximab in Crohn's (hazard ratio 1.85), while vedolizumab was lower than infliximab but not significantly so (Jensen 2023).

A different kind of cohort gives a much shorter number. The Canadian RECORDED study deliberately included only people who had been exposed to more than one advanced therapy. In its 330 people with Crohn's, the median time to permanent discontinuation of the first treatment was 12.3 months (Targownik 2025). That is what you would expect from a group chosen because they changed drugs. It should not be read as "biologics last a year". It describes people who switched.

Treatment records also hide how long a drug worked for the people who never appear in a switching study. The Canadian authors found that 58.1% of people with Crohn's had their first-line drug optimized (a higher dose or shorter interval) before it was permanently stopped, which fits with the common practice of adjusting before replacing.

How many biologics do people with Crohn's go through?

Most people in real-world datasets have one or two biologics over several years, and a smaller group has three or more. The best countable figure is from Italy, where 18.7% of first-time biologic users had changed more than once by year 5 (Pellegrini 2025). In Denmark, about one in four had more than one biologic during the study period (Jensen 2023).

What we could not find is a good, recent, Crohn's-specific number for how many people reach a third or fourth line, or how long the average person spends on each line. Anyone quoting a precise figure for "the average number of biologics" is probably quoting a single small cohort. The newer drug classes (risankizumab, guselkumab, mirikizumab and upadacitinib, a pill rather than a biologic) are too recent to have long switching histories in published registries, so older numbers may understate how many options now exist and overstate how fast people run out of them.

Lived experience in forums covers the full range. In a recent r/CrohnsDisease thread asking how many times people had switched (r/CrohnsDisease thread), answers ranged from people who had never switched to one person describing six different biologics over about ten years, with others reporting three changes in 17 years or a relative who has been on the same drug for more than three decades. The overall message of the replies was that it differs from person to person. That is anecdote, with the usual survivor bias (people on a stable drug post less), and it should not be used as evidence for any medical claim. It does match what the registries show: a wide range, with no standard number.

Why do people switch biologics for Crohn's disease?

The most common reason in the studies we found is that the drug no longer controlled the disease, but it is not the only one. In the Canadian RECORDED cohort, lack of efficacy was the most frequently cited reason for changing therapy in both Crohn's and UC (Targownik 2025). Beyond that, people change drug for several different reasons, and some of them have nothing to do with how well it worked.

Here is how the reasons usually divide:

  • The drug never worked (primary non-response). In the UK PANTS study, 23.8% of 1,241 assessable people starting infliximab or adalimumab for the first time had no response at week 14 (Kennedy 2019).
  • The drug worked and then faded (secondary loss of response). Among people in the PANTS three-year follow-up who had responded at first, the estimated share who later lost response was 34.4% at year 1, 54.5% at year 2 and 60.0% at year 3 on infliximab, and 32.1%, 47.2% and 68.4% on adalimumab. That definition was broad: it counted any need to escalate steroids, add an immunomodulator, raise the anti-TNF, have surgery, or leave the study for treatment failure (Chanchlani 2024). A review of 16 infliximab studies (2,236 people, 6,284 patient-years) put the annual risk of loss of response at about 13% per patient-year (Gisbert 2009).
  • Side effects or reactions. In PANTS, adverse events curtailed treatment in 7.8% of 1,610 people in the first year. In the extension years, 4% on infliximab and 5% on adalimumab had adverse events leading to withdrawal (Kennedy 2019, Chanchlani 2024).
  • Non-medical reasons. Insurance formularies, biosimilar substitution, changes of country or clinic, pregnancy planning and the wish for a less frequent injection or an easier schedule can all prompt a change. One person in the r/CrohnsDisease thread above described moving from infusions to injections partly because of how much simpler it made life. These reasons are hard to count in research, which is a real gap in the numbers.

PANTS and the other studies here define "failure" in different ways, so the percentages should be compared with care. Our companion article on what it means when a biologic stops working goes through the four mechanisms behind secondary loss of response and the tests used to tell them apart, so we will not repeat that here.

What do people try before switching?

Many people have the dose or interval of a biologic adjusted before it is replaced. In the Canadian cohort of 330 people with Crohn's, 58.1% of people with Crohn's had their first advanced therapy optimized before permanent discontinuation (Targownik 2025). The UK PANTS cohort also found that adding an immunomodulator was linked to a lower chance of developing anti-drug antibodies (hazard ratio 0.40 for infliximab, 0.42 for adalimumab) (Chanchlani 2024).

In a Danish randomized trial of 69 people who had lost response to infliximab, one group had the dose intensified and the other had treatment chosen by an algorithm based on drug and antibody levels. Response at week 12 was similar (58% with the algorithm, 53% with intensification) but costs were 34% lower with the algorithm (Steenholdt 2014). It is a small study, but it illustrates why a thread full of "get your levels tested" replies is not just forum folklore. Several people in the r/CrohnsDisease threads we read mentioned asking for drug level and antibody testing, and a few mentioned that insurance made those tests harder to get. Whether and when to test is a call for your clinician, and our article on why you need blood tests on a biologic explains what those results usually show.

None of this means a change is avoidable or unavoidable for you. It means the sequence in practice is usually test, adjust, then change if needed, and the numbers above count only the final step.

Is the second biologic less likely to work?

On average a second biologic works somewhat less often than the first, but the gap depends heavily on why the first one was stopped. A meta-analysis of 37 Crohn's studies of a second anti-TNF after infliximab found remission in 43% and response in 63% overall, but the figure varied by the reason for stopping: 61% after intolerance, 45% after secondary failure and 30% after primary non-response (Gisbert 2015). If you are comparing classes before a change, our guide to which biologic is best for Crohn's disease lays out how the guidelines and network meta-analyzes position each option.

Why the first anti-TNF was stoppedRemission with a second anti-TNFResponse
Intolerance61%72%
Secondary loss of response45%62%
Primary non-response30%53%
All reasons (Crohn's, after infliximab)43%63%

Most of those studies were small, uncontrolled and mostly looked at moving from infliximab to adalimumab, so the numbers are indicative rather than precise. The review itself noted that evidence for going from adalimumab to infliximab is thin.

The randomized evidence for switching within the anti-TNF class is older and narrower. In the GAIN trial of 325 people who had stopped infliximab because it had stopped working or caused side effects, 21% on adalimumab versus 7% on placebo were in remission at week 4 (Sandborn 2007). That trial was only four weeks long and did not look at maintenance.

How well do other drug classes work after an anti-TNF?

Trials in people who had already failed an anti-TNF show that the next class can work, with modest absolute numbers and a lot of variation between drugs and trials. Three examples with different designs are worth knowing.

Vedolizumab (GEMINI 3). Among 315 people with previous TNF antagonist failure, 15.2% on vedolizumab and 12.1% on placebo were in clinical remission at week 6, a difference that did not reach statistical significance. At week 10, remission was 26.6% versus 12.1% (Sands 2014). The authors' reading was that the benefit was slower to appear in this group.

Ustekinumab (UNITI-1). In 741 people with primary or secondary non-response to TNF antagonists, or unacceptable side effects, response at week 6 was 34.3% and 33.7% across the two doses versus 21.5% on placebo (Feagan 2016).

Risankizumab versus ustekinumab (SEQUENCE). This was an open-label head-to-head trial with blinded assessment of end points, in people with moderate-to-severe Crohn's who had inadequate response to, or intolerance of, anti-TNF therapy. Clinical remission at week 24 was 58.6% on risankizumab versus 39.5% on ustekinumab, and endoscopic remission at week 48 was 31.8% versus 16.2% (Peyrin-Biroulet 2024). Open-label design and short follow-up for some outcomes mean that it is one strong data point rather than the last word.

For real-world context, the UK IBD BioResource analyzed 13,222 people with IBD and found that, in Crohn's, non-anti-TNF biologics did better than a second anti-TNF after the first anti-TNF failed. The advantage was clearest in people whose first drug failed after a delayed loss of response or intolerance. The authors noted that their findings challenged current guidelines on drug selection after loss of response to a first anti-TNF (Kapizioni 2024). A second, smaller UK registry study of 180 people with Crohn's (the BISCUITS study) pointed the same way: people who moved to vedolizumab or ustekinumab were less likely to stop the new drug than those who moved to another anti-TNF, with an adjusted hazard ratio of 0.58 for discontinuation (Taylor 2025). Both are retrospective, and the BISCUITS cohort is small, so they show association, not proof.

Guidelines sit at a more cautious level. The 2025 AGA living guideline suggests that, for people who have previously been exposed to advanced therapy, adalimumab, risankizumab, guselkumab or upadacitinib (higher efficacy) or ustekinumab or mirikizumab (intermediate) be used rather than vedolizumab or certolizumab pegol (Scott 2025). The ACG's 2025 Crohn's guideline likewise stresses shared decision-making (Lichtenstein 2025). Both are population-level guidance. Neither tells a given person what to do next.

What happens to people in real life on a second or third biologic?

Persistence on second-line drugs is often reasonable, which is a useful counterweight to the "running out of options" fear. In a US claims study of ustekinumab, 74.8% of the 214 people with Crohn's were biologic-experienced, and 83.6% were still on treatment 12 months later (Obando 2020). Among those who stopped, 25.7% restarted and 8.6% switched within the year, and steroid and immunomodulator use fell after starting. That is a short follow-up in a database of 214 people, so it supports "many do well", not "most will".

The wording of that last point matters because forum threads can read as bleak. Reading the r/CrohnsDisease thread about changing biologics (r/CrohnsDisease thread), several people describe moving from one drug to another, and some report that the new one worked, while others describe a long run of changes. Nobody can tell from a post how common each outcome is, and registries answer that better.

How long do doctors wait between biologics?

There is no single waiting period, and timing is a prescriber decision that depends on the two drugs, how active the disease is and what the prescribing information says. A US insurance study of people with UC or Crohn's found that 64.2% of switches were "overlapping", meaning the next biologic started within five half-lives of stopping the old one. There was no significant difference in serious infection between overlapping and non-overlapping switches (adjusted hazard ratio 0.95), though this was observational (Kruger 2025).

Half-life is the time the body takes to clear half of a dose, so five half-lives is roughly when most of a drug has gone. The practical point for anyone reading this: do not shorten, lengthen or skip a washout on your own. Ask your IBD team how the overlap and timing will be handled for your two drugs, and whether anything needs to be checked before the first dose of the new one.

What are the limits of these numbers?

The numbers in this article are best read as ranges, not forecasts, because definitions, populations and drug choices differ between studies. Four limits apply to almost every figure above.

  1. Different definitions. "Switch", "swap", "discontinuation", "persistence" and "loss of response" mean different things in different papers. A claims database counts a gap in refills. A trial counts a CDAI score. PANTS counts steroid escalation.
  2. Mixed diseases. Several large datasets combine Crohn's and UC. UC and Crohn's behave differently, and the drug mix differs, so a combined percentage is only a rough guide to either.
  3. Moving targets. Biosimilars, subcutaneous infliximab, interleukin-23 drugs and upadacitinib changed the menu during or after many of these cohorts. Past switching rates reflect past options.
  4. Selection. People who stay on a drug disappear from "switching" studies, and people in forums are not a random sample. We found no study that gives a reliable number for "how many biologics will I personally need".

We also could not verify a figure for how often people who fail two or more biologics go on to remission, and we did not find a robust cohort for people on a fourth or later line, so we have left those out rather than guess.

What questions can you take to your IBD team?

If you are weighing a change, or just want to understand your own course, a short list of questions turns a vague worry into a useful appointment. None of these are instructions. They are prompts for your clinician.

  • Is my disease active right now, and how do we know (symptoms, blood markers, stool tests, imaging or colonoscopy)?
  • Has my drug level or antibody level been checked, and what did it show?
  • Is my dose or interval something we could look at first, or has that been tried already?
  • If a change were needed, which classes are options for me, and why?
  • Is a change being suggested for efficacy, side effects, insurance or another reason?
  • What would a washout or overlap look like for the two drugs?
  • What would we expect to see by week 12 or week 24 to judge the next drug?

Our guide on questions to ask your doctor about Crohn's disease has a broader list, and should you start biologics for mild Crohn's covers the earlier question of whether to begin one at all. For an infliximab-specific view of the trade-offs people report, see Remicade pros and cons for Crohn's.

Can tracking help when you are wondering whether to switch?

A dated record makes a switching conversation more concrete: "I have felt worse for a while" is hard to act on, while "my symptoms returned about three weeks after each of my last four infusions" is easier to assess. Useful things to log are bowel frequency and urgency, pain, night-time symptoms, steroid courses, flare dates, infusion or injection dates (including any late or missed doses), side effects and any test results you are given.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

In practice this is what the tracking angle comes down to: a timeline you can hand over, not a way to decide for yourself. Clairop's how it works page shows how symptom, medication and lab entries sit on one timeline, and the report is designed for sharing with your care team. It is not a diagnostic tool and cannot tell you whether a biologic has failed.

When should you talk to your IBD team promptly?

Do not wait for a routine appointment if symptoms change in a way that worries you. See a doctor promptly, or seek urgent care, for blood in the stool, a fever, severe or worsening abdominal pain, repeated vomiting, signs of dehydration, unexplained weight loss, new or worsening perianal pain or discharge, or symptoms after starting a new biologic such as a rash, swelling of the face or lips, or trouble breathing. Do not stop or skip a biologic on your own because of anything you have read here. Missing doses can bring on a flare, and restarting after a gap can sometimes cause reactions, which is a conversation for your prescriber.

Common myths about switching biologics

Myth: switching means the first drug "failed" and you did something wrong. Drug levels, immune antibodies, how inflammation is driven and non-medical reasons can all explain a change. Nothing in the studies above attributes it to diet or willpower.

Myth: everyone ends up switching. About half switched in five years in the Italian data, which also means about half did not. Several cohorts show a large group staying on one drug for years.

Myth: each switch is less likely to work than the last, so the options run out. Odds often go down somewhat, but they depend on the reason for the previous change and the new class, and there are now more classes than in most of these older studies.

Myth: a switch is always about efficacy. Side effects, access, biosimilar policy and convenience are all real drivers.

Myth: the numbers from a forum thread say how common it is. Threads attract people with something to say. Registries, with all their limits, are a better source.

The short version

If you have read the numbers and feel oddly reassured or alarmed, hold both. Switching is common enough that needing to is not a sign you did something wrong, and uncommon enough that you should not assume it is coming. The data say that a first biologic will not last forever for many people, that a second drug often works, and that the reason for the first drug stopping shapes what is likely next. The data cannot say what will happen for you. That call comes from your symptoms, your tests and your IBD team, not from an average.

Frequently asked questions

How often do people switch biologics for Crohn's disease?
It depends on the study, but it is common. In an Italian database of 28,073 people starting a biologic for IBD (56% with Crohn's), 12.0% had switched or swapped drugs by 1 year, 35.6% by 3 years and 52.6% by 5 years. Other cohorts report lower figures because they count differently, follow people for less time, or include people who stay on one drug for many years.
How many biologics will I need for Crohn's disease?
No one can say in advance. Some people stay on their first biologic for a decade or more, and others go through several. In the Italian cohort, about 18.7% of people had changed biologic more than once within 5 years. In a Danish registry of people with IBD, about one in four had more than one biologic during the 2015 to 2020 study period.
How long does the first biologic usually last in Crohn's disease?
There is no single answer. In a US claims study of 2,309 people with Crohn's, 3-year persistence was 48% for infliximab, 52% for adalimumab, 58% for vedolizumab and 61% for ustekinumab, with no adjustment for differences between patients. In a Canadian cohort selected because people had tried more than one advanced therapy, the median first-line treatment lasted 12.3 months.
What is the difference between a switch and a swap?
Researchers usually call a change to another drug in the same class a switch (for example one anti-TNF to another) and a change to a different class a swap (for example an anti-TNF to ustekinumab). The Italian VALORE study counted both and used a separate term for moving from a biosimilar back to the original brand. Check how a study defines these before comparing numbers.
Is the second biologic less likely to work than the first?
Often somewhat less likely, but it depends on why the first was stopped. In a meta-analysis of a second anti-TNF after infliximab failed in Crohn's, remission was reached in 61% when the first drug was stopped for side effects, 45% after secondary loss of response and 30% after primary non-response. Other classes have their own trial data after anti-TNF failure.
Do people only switch biologics because they stopped working?
No. Loss of efficacy is the most common reason in the studies we found, but side effects, infusion reactions, access, insurance formularies, biosimilar switches, pregnancy planning and convenience also lead to changes. In a US insurance database, 1,293 of 11,992 people starting a biologic for UC or Crohn's switched at least once, and the study did not separate every reason.
How long should there be between stopping one biologic and starting another?
That is decided by your prescriber and depends on the drugs and your situation. A US insurance study of people with UC or Crohn's found that 64.2% of switches began within 5 half-lives of the previous drug, and infection risk was not significantly different from longer gaps, but it is an observational study and not a guide to timing for any one person.
What is the best way to track whether a biologic is working before a switch discussion?
Clairop works well for this because it keeps symptoms, bowel pattern, dose dates and any test results on one timeline you can show your gastroenterologist. Dated notes make it easier to say when symptoms came back relative to doses. It does not tell you whether to change drugs, which is a decision for your care team.
Do biologics work after a switch to a different class?
Often they do. In the UNITI-1 trial, 34.3% of people who had failed or could not tolerate an anti-TNF had a response to ustekinumab at week 6, against 21.5% on placebo. In the SEQUENCE trial in the same population, 58.6% on risankizumab and 39.5% on ustekinumab reached clinical remission at week 24. Results vary between studies.
Should I change my biologic if I read that people switch often?
No. Population averages say nothing about your own disease. A change should follow a conversation with your IBD team, usually with tests that show whether inflammation is active and what is happening with drug levels. Never stop or change a biologic on your own because of statistics you read online.

Sources

  1. Pellegrini G, Spini A, Bellitto C, L'Abbate L, Ingrasciotta Y, Soardo F, et al. Single and multiple switches, swap and retransitioning among 28,073 biological drug users with inflammatory bowel diseases: results from the Italian VALORE network. Therap Adv Gastroenterol. 2025;18:17562848251378080. doi:10.1177/17562848251378080
  2. Targownik L, Afif W, Singh S, et al. Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis. J Can Assoc Gastroenterol. 2025;8(1):21-30. doi:10.1093/jcag/gwae040
  3. Jensen KJ, Jensen CB, Wennerstrom C, et al. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020. Scand J Gastroenterol. 2023;58(7):726-36. doi:10.1080/00365521.2023.2173988
  4. Zhao R, Ding Z, Gupta P, Gozalo L, Bruette R, Johnson VM, et al. Evaluation of treatment patterns and maintenance dose titration among patients with Crohn's disease initiating biologics with 3 years of follow-up. J Health Econ Outcomes Res. 2023;10(2):111-20. doi:10.36469/001c.88947
  5. Kruger AJ, Dormont F, Capit N, Schilsky S, Roberts A, Lin Y, et al. Biologic switch timing and risk of infection in patients with ulcerative colitis/Crohn's disease: a retrospective study. Clin Gastroenterol Hepatol. 2025;23(12):2253-62. doi:10.1016/j.cgh.2025.01.028
  6. Kapizioni C, Desoki R, Lam D, et al. Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource. J Crohns Colitis. 2024;18(6):790-800. doi:10.1093/ecco-jcc/jjad203
  7. Taylor F, Bartalucci G, Gleave C, et al. Real-world outcomes from the UK IBD Registry on second-line biologic therapy following anti-TNF exposure in Crohn's disease: results from the BISCUITS study. Therap Adv Gastroenterol. 2025;18:17562848251352446. doi:10.1177/17562848251352446
  8. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341-53. doi:10.1016/S2468-1253(19)30012-3
  9. Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9(6):521-38. doi:10.1016/S2468-1253(24)00044-X
  10. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104(3):760-7. doi:10.1038/ajg.2008.88
  11. Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613-23. doi:10.1111/apt.13083
  12. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-38. doi:10.7326/0003-4819-146-12-200706190-00159
  13. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618-27.e3. doi:10.1053/j.gastro.2014.05.008
  14. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60. doi:10.1056/NEJMoa1602773
  15. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease. N Engl J Med. 2024;391(3):213-23. doi:10.1056/NEJMoa2314585
  16. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919-27. doi:10.1136/gutjnl-2013-305279
  17. Scott FI, Ananthakrishnan AN, Click B, et al. AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn's disease. Gastroenterology. 2025;169(7):1397-448. doi:10.1053/j.gastro.2025.09.038
  18. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225-64. doi:10.14309/ajg.0000000000003465
  19. Obando C, Ding Z, Muser E, et al. Persistence, dose titration, and health care resource utilization among Crohn's disease patients treated with ustekinumab: a real-world analysis in the United States. Adv Ther. 2020;37(5):2127-43. doi:10.1007/s12325-020-01276-3

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools